1. Jiangsu's Scale and Position in China's Pharmaceutical Industry

In China's pharmaceutical manufacturing landscape, Jiangsu holds a lead that is both large in scale and meaningful in quality — and neither advantage is marginal.

In 2023, Jiangsu's above-scale pharmaceutical manufacturers recorded revenue of RMB 322.1 billion, placing the province first nationally and accounting for approximately 12.9% of China's total pharmaceutical manufacturing revenue. The second-ranked province, Shandong, came in at approximately RMB 285.3 billion — Jiangsu's lead exceeded RMB 36 billion. This gap does not rest on a single dominant company; it reflects a system-level contribution across chemical drugs, biologics, medical devices, and active pharmaceutical ingredients (APIs) operating in parallel.

By 2024, the advantage had widened further. Jiangsu's biopharmaceutical cluster achieved annual revenue of RMB 454.4 billion and total profits of RMB 73.0 billion — representing 15.1% and 17.9% of the national totals respectively, both ranking first in China. Revenue expanded by more than 40% within a single year, a pace that is unusual for a manufacturing-dominant province at this scale.

At the enterprise level, Jiangsu placed 15 companies in the 2023 China Pharmaceutical Industry Top 100 (ranked by primary business revenue) — the highest count of any province — with 8 of them in the top 50. Within the province, Lianyungang had the most entrants at four. This breadth signals a multi-city structure rather than a single-pole concentration, and it distinguishes Jiangsu from provinces whose pharmaceutical rankings rest on one or two flagship enterprises.

2. Lianyungang: An Innovation-Drug Cluster Built on Saline Flats

In China's pharmaceutical map, Lianyungang occupies a position that punches well above its urban scale. The city lacks the capital resources of Shanghai or Beijing, and lacks the foreign-investment base of Suzhou Industrial Park. Yet in innovation drugs — the hardest path in the industry — it has built a profile that is recognizable nationally.

The cluster's anchor is Hengrui Medicine. In 2023, Hengrui reported revenue of RMB 22.82 billion, up 7.3% year-on-year. Total R&D expenditure reached RMB 6.15 billion, with the expensed portion at RMB 4.95 billion — representing approximately 27% of revenue. This R&D intensity ranks high even by global standards for pharmaceutical companies of comparable scale. Innovation-drug revenue crossed RMB 10 billion for the year, accounting for close to half of total revenue. Hengrui's trajectory is the story of a traditional generic-drug maker systematically transforming itself into an innovation-driven enterprise through sustained, high-density research investment over two decades.

Sharing the Lianyungang Economic Development Zone, Hansoh Pharmaceutical (parent of Haosen) recorded innovation-drug and partner-product revenue exceeding 61.8% of total sales in 2023. Chia Tai Tianqing has progressively broadened its approved product lines in hepatology and oncology. Altogether, the zone hosts four companies in China's pharmaceutical Top 100, six listed entities, and over 40 R&D, manufacturing, and service projects in the core area of China Pharmaceutical Port.

The quality metrics are even more telling than the counts. In 2023, China approved 16 Class-I new chemical entities in total; Lianyungang companies contributed 3 of them — approximately 18.8% of the national total — from a single prefecture-level city. Of the 149 innovation drugs in the National Medical Insurance Directory, Lianyungang companies supplied 31, or over 20%. These figures place Lianyungang's innovation output in a league of its own among China's prefectural cities.

The root cause is decades of commitment to staying local. Hengrui, Hansoh, and Chia Tai Tianqing all kept their core R&D operations in Lianyungang through successive growth cycles, gradually building a shared talent pool, shared regulatory familiarity, and a shared academic network that now produces genuine cluster-level spillovers.

3. Taizhou China Pharmaceutical City: A Decade of Building a Full-Chain Park

Taizhou's pharmaceutical strategy is built on a different premise: rather than cultivating homegrown champions, it constructed a platform designed to lower friction across the entire drug development value chain and give domestic and international pharmaceutical companies a reason to converge in one place.

China Pharmaceutical City (Taizhou Pharmaceutical High-Tech Zone) crossed the RMB 120 billion threshold in large-health industry scale in 2023 — the same year it first entered the national top 10 ranking for comprehensive competitiveness among biopharmaceutical industrial parks. By the end of 2024, it had maintained a top-10 position for two consecutive years. The park now hosts over 1,300 pharmaceutical and health enterprises, 14 globally recognized multinational drugmakers, and more than 4,300 high-level domestic and international professionals.

The logic behind these numbers is to concentrate the full sequence from preclinical research to GMP manufacturing, and from device registration to commercialization, in a single administrative footprint — minimizing the transaction costs that ordinarily slow drugs from discovery to market. The park's competitive advantage is not the density of original research, but the end-to-end reduction of development friction.

Yangzijiang Pharmaceutical, one of Taizhou's leading chemical-drug companies, has maintained a long-standing position in the China pharmaceutical Top 100 rankings. The zone also has a dedicated cluster in synthetic biology: in 2023 its synthetic biology industry scale reached approximately RMB 6 billion.

4. Suzhou: The Commercialization Node for Biomedical Innovation

Suzhou's role in Jiangsu's pharmaceutical landscape differs from both Lianyungang and Taizhou. It is the highest-efficiency node for converting biomedical research into commercial-scale production — built on a foundation of foreign biotechnology enterprise concentration in Suzhou Industrial Park, with domestic innovation-drug companies accumulating on top of that base.

In 2023, Suzhou's biopharmaceutical industry reached approximately RMB 330 billion in scale, with above-scale pharmaceutical manufacturing industrial output value of approximately RMB 68 billion. Suzhou Industrial Park is the only biopharmaceutical cluster in Jiangsu to receive an "Outstanding" rating in the national Strategic Emerging Industry Cluster evaluation. In terms of commercial output, PD-(L)1 antibody drugs from companies based in the park generated approximately RMB 4.9 billion in sales in 2023, representing roughly 40% of the national market for that product class — a level of concentration that indicates genuine cluster-level competitive strength in immuno-oncology.

Suzhou's model is structurally complementary to Lianyungang's: Lianyungang built its innovation capacity by keeping homegrown traditional pharma companies rooted locally through a long transformation; Suzhou built its through high-density attraction of international biotech firms and domestic incubation. The two cities draw on different talent profiles, capital structures, and product pipeline orientations, together anchoring Jiangsu's pharmaceutical innovation map from opposite ends.

Nanjing, the provincial capital, is a third major node: in 2023, the city's biopharmaceutical industry recorded RMB 200.8 billion in revenue, up approximately 10.2%, with manufacturing output value of RMB 53.2 billion. The city's cluster is organized around Jiangbei New Area as its core, with complementary development across Jiangning, the Economic Development Zone, Qixia, and Gaochun districts.

5. The API Foundation: Unglamorous but Structurally Indispensable

Jiangsu's API sector rarely captures headlines in discussions about innovation drugs, but it is the load-bearing base beneath the entire value chain.

The province hosts over 225 API manufacturing enterprises — the highest count in China. APIs are not merely commodity chemicals: they are the upstream material input for finished-dose manufacturing, drug innovation, and generic-drug bioequivalence qualification. Any downstream product requiring large-scale commercial supply depends on a reliable, quality-controlled API supply chain. Jiangsu's API base gives its finished-drug and innovation-drug sectors supply-chain resilience, and it is one of the reasons Jiangsu pharmaceutical companies remain competitive in international markets.

On the trade side, Jiangsu is perennially one of China's three largest pharmaceutical exporting provinces, alongside Guangdong and Shanghai. API export competitiveness reflects decades of accumulated capability in quality management and cost discipline among Jiangsu's traditional pharmaceutical manufacturers.

6. Headwinds: Volume-Based Procurement Pressure, R&D Intensity Gaps, and Cross-City Integration

The strengths above coexist with several structural challenges that deserve direct acknowledgment.

The first is the continued expansion of China's national volume-based drug procurement (集采) program. Since 2019, the program has covered more than 435 drug types, with average price reductions of 52%. For the many mid-sized Jiangsu pharmaceutical manufacturers whose portfolios are centered on generic drugs, this creates a dual pressure: compressed margins on existing products, and the need to reconstruct product competitive positions. The price-for-volume dynamic in generics is pushing some firms toward innovation and others toward further integration into the API supply chain.

The second is the wide dispersion in R&D intensity across the provincial enterprise base. Hengrui, Hansoh, and a small number of other leading firms operate with R&D expense ratios above 20%. The majority of small and medium-sized pharmaceutical manufacturers in Jiangsu still focus primarily on generic bioequivalence qualification rather than new molecular entity (NME) programs. Innovation output is highly concentrated in a small number of large companies; the transformation path for the middle and long tail of the industry remains an open question.

The third is the coordination gap across the four poles. Lianyungang, Taizhou, Suzhou, and Nanjing operate with distinct industrial orientations, talent strategies, and regulatory service capabilities. Provincial-level integration mechanisms are still being built. Cross-city supply-chain linkages and commercialization support are less developed than within-cluster capabilities, and this represents a structural gap relative to the more integrated ecosystems in some competing regions.

For upstream suppliers selling into Jiangsu pharmaceutical factories, these headwinds are not only risk signals — they are also indicators of timing. A generic-drug factory under margin pressure from volume-based procurement is typically more receptive to discussions about excipient substitution, process equipment upgrades, and quality system improvements than a factory operating in a comfortable margin environment.

7. Research Institute Assessment

Jiangsu's pharmaceutical manufacturing position can be described in one sentence: first in scale nationally, with a clearly tiered innovation structure still in progress of maturation.

The top tier is represented by Lianyungang's Hengrui and Hansoh — R&D-driven enterprises that have largely completed the transition from generics to innovation drugs and have begun to claim a visible position in the global innovation-drug landscape. The middle tier is represented by the platform-and-ecosystem approach of Taizhou's pharmaceutical park and Suzhou Industrial Park's incubation model, where commercial scale-up is accelerated by infrastructure and regulatory service concentration. The base tier is a large population of small-to-medium pharmaceutical companies still centered on generics and APIs, which will work through a longer adjustment period as policy headwinds persist.

This tiered structure is not unique to Jiangsu, but it manifests most clearly here: the overall scale is large enough that each tier has meaningful critical mass, and the gradient is distinct enough that enterprises operating on different strategic logics coexist within the same provincial boundary. The two questions most worth watching over the next five years: whether Lianyungang's innovation drugs can achieve meaningful commercial volume through licensing and direct sales in overseas markets; and whether Suzhou Industrial Park's biotech pipeline can continue generating domestic NME approvals at the current pace. The first will determine Jiangsu's weight in the global innovation-drug map; the second will determine the quality of Jiangsu's next-generation pharmaceutical cluster.

Tianxia Gongchang aggregates the factory directory and verified decision-maker contacts for Jiangsu's pharmaceutical manufacturing sector, covering chemical finished-dose manufacturers, API producers, biologics facilities, pharmaceutical equipment makers, and pharmaceutical packaging companies. For upstream sales professionals supplying raw materials, excipients, manufacturing equipment, or testing services to Jiangsu's pharmaceutical factories, Tianxia Gongchang enables precise filtering by geography and sub-sector, turning factory-by-factory prospecting into a structured, scalable process.

Data Sources

  • Tianxia Gongchang (Jiangsu pharmaceutical manufacturing factory directory and industry data)
  • PharmaRDA: "Above-Scale Pharmaceutical Manufacturer Revenue Rankings: Which Province Leads China's Biomedical Sector?"
  • Jiangsu Provincial Department of Industry and Information Technology: "15 Jiangsu Enterprises Selected to China Pharmaceutical Industry Top 100 — Province Ranks First Nationally" (September 2024, )
  • CPC Jiangsu Provincial Committee News Network: "From 'China New' to 'Global New' — Lianyungang Pharmaceutical Industry Advances Toward Thousand-Billion 'China Pharmaceutical Port'" (March 2024, )
  • Hengrui Medicine 2023 Annual Report (China News Service Shanghai: )
  • CPC Jiangsu Provincial Committee News Network / Taizhou: "China Pharmaceutical City's Large-Health Industry Scale Exceeds RMB 120 Billion" (November 2024, )
  • Suzhou Municipal People's Government: "Suzhou Industrial Park Biopharmaceutical and Healthcare Industry Scorecard" (February 2024, )
  • Nanjing Municipal People's Government: "Nanjing's Practice of High-Quality Biopharmaceutical Development" (July 2024, )
  • The Paper / CPC Jiangsu Committee News: "First, Third, Sixth, and Seventh — All from Lianyungang"